Axsome Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2015 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Axsome Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2015 to Q4 2023.
  • Axsome Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $223M, a 21.2% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $223M +$39M +21.2% Dec 31, 2023 10-K 2024-02-23
Q4 2022 $184M +$26.9M +17.1% Dec 31, 2022 10-K 2024-02-23
Q4 2021 $158M +$49.6M +45.9% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $108M +$39.7M +58.1% Dec 31, 2020 10-K 2022-03-01
Q4 2019 $68.3M +$27M +65.5% Dec 31, 2019 10-K 2021-03-01
Q4 2018 $41.3M +$12.4M +43.1% Dec 31, 2018 10-K 2020-03-12
Q4 2017 $28.8M +$6.76M +30.6% Dec 31, 2017 10-K 2019-03-15
Q4 2016 $22.1M +$14.3M +185% Dec 31, 2016 10-K 2019-03-15
Q4 2015 $7.76M Dec 31, 2015 10-K 2018-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.